ENTPD1 and neoplasm: Similarly, Wu et al. described a cancercell-derived exosome-based nanodelivery system (C-PMet) to boost innateand adaptive tumor immunity by inhibiting the ATP–adenosineaxis (Table 5).183 This nanosystem achieved tumor-selective deliveryof CD39 antagonist (POM1) and AMPK agonist (Met), and prevented severeimmune-related adverse events.